Lly stock forecast current LLY stock forecast analysis

Current LLY stock forecast analysis shows volatility is trending lower, a bullish sign for long-term holders. Hedge fund ownership has climbed 12% this quarter, betting on Eli Lilly’s dominance in metabolic disease therapies. Price action suggests consolidation in the $800–$820 range before another rally leg. Overall, on Wall Street, Novo Nordisk stock is a “Moderate Buy.” Of the 20 analysts who cover the stock, nine rate it a “Strong Buy,” nine say it is a “Hold,” one says it is a “Moderate Sell,” and one suggests a “Strong Sell.” The average analyst price target of $65.88 suggests an 18.5% increase from current levels. Furthermore, the Street-high estimate of $112 implies that the stock could rally by up to 101.4% over the next year. I agree to TipRanks Terms of use and Privacy Policy LLY stock forecast outlook strengthened after EU regulatory approval for tirzepatide. Revenue forecasts adjusted upwards to $50B by 2026, marking one of the fastest growth trajectories in pharma history.